• Fluoxetine HCl Workflows for Motivation Research

  2026-08-22

  Fluoxetine HCl supports controlled studies of serotonin transport, 5-HT2C signaling, and reward-related phenotypes from membrane assays to animal behavior. This workflow separates acute serotonergic pharmacology from developmental SSRI effects, helping researchers interpret motivation, neurogenesis, and synaptic plasticity results more rigorously.

• Melatonin, RIPK3, and Atrazine-Induced Kidney Injury

  2026-08-22

  The reference study identifies RIPK3-dependent necroptosis as a central mechanism of atrazine-induced renal injury and shows that melatonin suppresses this pathway across in vivo and in vitro models. Its combination of pathway analysis, RIPK3 knockdown, and computational modeling provides a useful framework for distinguishing antioxidant protection from direct regulation of necroptotic signaling.

• Carfilzomib Sensitizes ESCC to Iodine-125 Radiation

  2026-08-21

  This 2025 Translational Oncology study shows that Carfilzomib, also known as PR-171, intensifies iodine-125 seed radiation responses in esophageal squamous cell carcinoma through coordinated apoptosis, paraptosis, and ferroptosis. The work links proteasome inhibition to aggravated endoplasmic reticulum stress and provides a mechanistic framework for studying radiosensitization rather than treating cell death as a single-pathway event.

• ALDH2 Inhibition in APC-Deficient Colorectal Cancer

  2026-08-20

  Liang et al. identify ALDH2 inhibition as a genotype-selective vulnerability in APC-deficient colorectal cancer, with Disulfiram treatment increasing ROS and activating the ASK1/JNK apoptotic pathway. The study combines computational screening, cell-based phenotyping, mechanistic assays, and xenograft validation to support a synthetic-lethal strategy for APC-mutant tumors.

• 3-Hydroxybutyrate (BHBA) in Neuroprotection

  2026-08-20

  Use 3-hydroxybutyrate (BHBA) as a controlled ketone-body add-back to dissect neuronal energy metabolism, ferroptosis resistance, and chromatin signaling. This workflow separates direct metabolite effects from whole-body ketosis and remote ischemic conditioning, improving mechanistic resolution in stroke and metabolic disease research.

• ALDH2–APC Synthetic Lethality in Colorectal Cancer

  2026-08-19

  The reference study identifies ALDH2 inhibition with disulfiram as a potential synthetic-lethal strategy for APC-deficient colorectal cancer, linking APC loss to ROS accumulation and ASK1/JNK-driven apoptosis. Its paired cell-model and xenograft findings provide a framework for genotype-informed cancer research while also emphasizing the need to separate ALDH2-dependent effects from disulfiram’s broader pharmacology.

• NU6300 Targets GSDMD Cysteine-191 and Pyroptosis

  2026-08-19

  Jiang et al. identify NU6300 as a covalent gasdermin D inhibitor that reacts with cysteine-191, suppressing GSDMD cleavage, palmitoylation, membrane recruitment, and pore formation. The study connects this mechanism with reduced pyroptotic inflammation and protection in experimental colitis and sepsis, while revealing pathway-specific differences between AIM2, NLRC4, and NLRP3 inflammasomes.

• Syringin Workflow for RCC Combination Research

  2026-08-18

  Syringin offers a practical natural-product entry point for RCC phenotypic screening, apoptosis research, and sunitinib-sensitization studies. This workflow connects solvent-controlled dose testing with EGFR/PI3K/Akt pathway validation, helping researchers distinguish genuine combination effects from assay artifacts.

• DiI (DiIC18(3)) Plasma Membrane Probe Guide

  2026-08-18

  DiI (DiIC18(3)) provides orange-red labeling of plasma membranes in live or fixed cells and tissues, supporting neuronal tracing, migration, adhesion, fusion, and lipoprotein workflows. It is water-insoluble and should not be treated as a general cytoplasmic or organelle stain; solvent selection, membrane integrity, fixation, and imaging controls are essential.

• ONX-0914: Immunoproteasome Biology Beyond the Cell

  2026-08-17

  ONX-0914 (PR-957) is a selective LMP7 inhibitor for dissecting cytokine signaling and immunoproteasome function. This article adds an extracellular-vesicle perspective, showing how intercellular proteasome transfer can influence assay interpretation in autoimmune, arthritis, and diabetes research.

• MG-262: Reversible Proteasome Inhibitor

  2026-08-17

  MG-262, also called Z-Leu-Leu-Leu-B(OH)2, is a reversible, cell-permeable boronic peptide acid that inhibits proteasome chymotryptic activity. It provides a controlled perturbation tool for proteasome inhibition assay design, apoptosis research, and studies connecting ubiquitin-dependent degradation with skeletal muscle proteostasis.

• ONX-0914 (PR-957) Workflow for Immune Assays

  2026-08-16

  ONX-0914 (PR-957) enables selective LMP7-focused immunoproteasome inhibition for cytokine, PBMC, and autoimmune disease model workflows. This guide combines practical dosing, assay controls, and troubleshooting with a cautious neuroimmune bridge inspired by cortical synaptic research.

• ONX-0914: From LMP7 Selectivity to CNS Assays

  2026-08-15

  ONX-0914 (PR-957) is best known for selective immunoproteasome inhibition in autoimmune models. This article develops a distinct assay-centered framework linking LMP7 target engagement, cytokine production blockade, chronic exposure, and hippocampal synaptic-plasticity measurements.

• JNJ-26854165 (Serdemetan) Assay Workflows

  2026-08-14

  Build more informative p53-pathway experiments with JNJ-26854165 (Serdemetan), combining growth-inhibition measurements with apoptosis-specific and radiation-response readouts. This workflow separates cytostatic effects from true cell killing while addressing solubility, timing, genotype, and assay-design challenges.

• MG-262 for Muscle Proteostasis Assay Design

  2026-08-14

  MG-262 and Z-Leu-Leu-Leu-B(OH)2 provide a reversible, cell-permeable way to interrogate proteasome function without confusing it with chaperone-mediated autophagy. This guide translates new skeletal-muscle CMA findings into more rigorous proteasome inhibition assay design and interpretation.

8522 records 1/569 page Next 12345 下5页 Last page